Physician profile
Robert S Baer
NPI 1083720767
$302,504.87
in general payments reported to CMS, 2019-2025
37 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103K · 2020: $39K · 2021: $49K · 2022: $53K · 2023: $33K · 2024: $23K · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Food and Beverage: $7,494 · Travel and Lodging: $1,516 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,384.83 |
| Food and Beverage | $7,493.53 |
| Travel and Lodging | $1,515.61 |
| Education | $299.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106,121.19 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $81,917.51 | 2019-2025 | Dupixent |
| Genzyme Corporation | $63,229.37 | 2019-2025 | |
| Dermavant Sciences, INC. | $16,990.90 | 2022-2024 | Vtama |
| Amgen INC. | $9,847.85 | 2019-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $6,665.85 | 2019-2025 | |
| Celgene Corporation | $6,421.21 | 2019 | |
| Ucb, INC. | $4,439.82 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,340.97 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $748.58 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $588.90 | 2019-2025 | |
| Lilly USA, LLC | $570.20 | 2019-2025 | Ebglyss |
| Leo Pharma INC. | $531.10 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $471.37 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $443.05 | 2023-2025 | Zoryve |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $391.58 | 2019-2025 | Nemluvio, Epsolay |
| Vyne Pharmaceuticals INC. | $359.45 | 2020-2021 | |
| Incyte Corporation | $252.13 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $234.22 | 2019 | |
| Biofrontera INC. | $178.16 | 2019-2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $176.15 | 2020-2021 | |
| Genentech USA, INC. | $110.87 | 2019-2021 | |
| Helsinn Therapeutics (U.S.), INC. | $53.03 | 2020-2025 | Valchlor |
| Dusa Pharmaceuticals, INC. | $48.92 | 2019 | |
| Sandoz INC. | $43.16 | 2024 | Hyrimoz |
| Verrica Pharmaceuticals INC. | $39.06 | 2023 | Ycanth |
| Taro Pharmaceuticals USA, INC. | $38.63 | 2019 | |
| Aclaris Therapeutics, INC. | $37.40 | 2019 | |
| Journey Medical Corporation | $35.65 | 2022 | |
| Epi Health, LLC | $31.21 | 2020-2021 | |
| Organon LLC | $28.95 | 2024-2025 | Vtama |
| Springworks Therapeutics, INC. | $27.96 | 2025 | Gomekli |
| Lnhc, INC | $21.88 | 2025 | Zelsuvmi |
| Kyowa Kirin, INC. | $21.53 | 2022 | |
| Almirall LLC | $19.30 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.44 | 2019 | |
| Convatec INC. | $13.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Baer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.